Replies to post #287 on Zosano Pharma Corp. (fka ZSANQ)

[Triple9]

Last news was Feb 13:

Zosano Pharma Announces 3.8mg Dose of M207, its Novel Transdermal Therapeutic, Meets Both Co-primary Endpoints in the ZOTRIP Pivotal Efficacy Trial in Migraine

http://ir.zosanopharma.com/releasedetail.cfm?ReleaseID=1011563